EP1656128A4 - Acne vulgaris-behandlung und verwendungsverfahren - Google Patents

Acne vulgaris-behandlung und verwendungsverfahren

Info

Publication number
EP1656128A4
EP1656128A4 EP03818329A EP03818329A EP1656128A4 EP 1656128 A4 EP1656128 A4 EP 1656128A4 EP 03818329 A EP03818329 A EP 03818329A EP 03818329 A EP03818329 A EP 03818329A EP 1656128 A4 EP1656128 A4 EP 1656128A4
Authority
EP
European Patent Office
Prior art keywords
treatment
acne vulgaris
ethoxylate
composition
exchanged
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03818329A
Other languages
English (en)
French (fr)
Other versions
EP1656128A1 (de
Inventor
William M Yarbrough
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
William M Yarbrough Foundation
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1656128A1 publication Critical patent/EP1656128A1/de
Publication of EP1656128A4 publication Critical patent/EP1656128A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to a composition including surfactants for the treatment of acne vulgaris. Methods of use are also included ⁇ . BACKGROUND OF THE INVENTION AND PRIOR ART Acne vulgaris (or "acne") is a disorder of the sebaceous glands. It is characterized by lesions that are either non-inflammatory or inflammatory papules and nodules. Non-inflammatory papules may be open, commonly referred to as “blackheads", or closed, commonly referred to as “whiteheads”. As a group, non- inflammatory papules are called comedones.
  • a topical treatment for acne 5 vulgaris a topical treatment for acne 5 vulgaris.
  • a method is provided for applying a composition of 6 substances to the infected area, working the composition into the infected area, and 7 removing the composition from the infected area.
  • the composition comprises at least 8 one ethoxylate in combination with Sodium Lauroyl Sarcosinate (or "SLS").
  • SLS Sodium Lauroyl Sarcosinate
  • An inert 9 scrubbing agent such as polyethylene beads, can also be included to the formula.
  • Acetylated lanolin alcohol, a second ethoxylate, EDTA, a foam stabilizer, and water can 11 also be added to the composition without effecting performance.
  • Other formulas that keep the polarity similar to that of the inventive formula will 13 also work. To keep the polarity similar, it is necessary for the compound to have similar 14 characteristics, such as Carbon chains, carbonyl groups, Nitrogen bound to Carbon, 15 Aromatic ring(s), Oxylate groups, and appropriate functional groups at the ends of the 16 individual molecules.
  • the ideal substitute chemicals would have all of the characteristics 17 mentioned above, but it is not necessary to have every one of those as listed.
  • the cutting agent must be added only in 2 sufficient amount that it promotes flow but does not effect the action of the composition. 3
  • an sufficient amount of the composition is used to cover the infected area, 4 the composition is applied to an infected area and worked over the area by a scrubbing 5 motion. After sufficient time has elapsed to ensure that the infected area has been 6 adequately exposed to the composition such that they area feels clean, approximately ten 7 to thirty seconds for the typical person, the area is rinsed cleaned.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EP03818329A 2003-08-12 2003-08-12 Acne vulgaris-behandlung und verwendungsverfahren Withdrawn EP1656128A4 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/025207 WO2005018629A1 (en) 2003-08-12 2003-08-12 Treatment for acne vulgaris and method of use

Publications (2)

Publication Number Publication Date
EP1656128A1 EP1656128A1 (de) 2006-05-17
EP1656128A4 true EP1656128A4 (de) 2007-02-28

Family

ID=34215304

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03818329A Withdrawn EP1656128A4 (de) 2003-08-12 2003-08-12 Acne vulgaris-behandlung und verwendungsverfahren

Country Status (5)

Country Link
EP (1) EP1656128A4 (de)
JP (1) JP2007521234A (de)
AU (1) AU2003264053A1 (de)
CA (1) CA2535550A1 (de)
WO (1) WO2005018629A1 (de)

Families Citing this family (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007336243B2 (en) 2006-12-19 2012-07-26 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
CA2673331A1 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
FR2923383B1 (fr) * 2007-11-08 2010-03-19 Oreal Utilisation d'un sarcosinate n-acyle comme agent anti-adhesion microbienne.
WO2009068631A1 (de) 2007-11-27 2009-06-04 Ablynx N.V. Verfahren und vorrichtung zum herstellen, insbesondere zum runderneuern, von reifen
CA2717015A1 (en) 2008-03-05 2009-09-11 Ablynx Nv Novel antigen binding dimer-complexes, methods of making and uses thereof
AU2009235467A1 (en) 2008-04-07 2009-10-15 Ablynx Nv Single variable domains against the Notch pathways
NZ589036A (en) 2008-05-16 2012-07-27 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
HUE042053T2 (hu) 2008-06-05 2019-06-28 Ablynx Nv Vírus burokfehérjéi elleni aminosav-szekvenciák és az azokat tartalmazó polipeptidek virális betegségek kezelésére
WO2010043650A2 (en) 2008-10-14 2010-04-22 Ablynx Nv Amino acid sequences directed against cellular receptors for viruses and bacteria
EP2364328A2 (de) 2008-12-10 2011-09-14 Ablynx NV Gegen das angiopoietin/tie-system gerichtete aminosäuresequenzen und diese enthaltende polypeptide zur behandlung von mit angiogenese in zusammenhang stehenden krankheiten und störungen
WO2010100135A1 (en) 2009-03-05 2010-09-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
US8748581B2 (en) 2009-04-10 2014-06-10 Ablynx N.V. Anti-IL-6R polypeptides and pharmaceutical compositions thereof
HUE053480T2 (hu) 2009-04-30 2021-06-28 Ablynx Nv Eljárás domén ellenanyagok elõállítására
KR101852204B1 (ko) 2009-06-05 2018-04-26 아블린쓰 엔.브이. 기도 감염의 예방 및/또는 치료를 위한 일가, 이가 및 삼가 항 인간 호흡기 세포융합 바이러스 (ｈｒｓｖ) 나노바디 구조물
US9150640B2 (en) 2009-07-10 2015-10-06 Ablynx N.V. Method for the production of variable domains
LT2805731T (lt) 2009-09-03 2019-02-11 Ablynx N.V. Stabilios polipeptidų kompozicijos ir jų panaudojimas
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
HRP20251657T1 (hr) 2009-12-14 2026-02-13 Ablynx N.V. Imunoglobulinska protutijela s jednostrukom varijabilnom domenom protiv ox40l, konstrukti i njihova terapijska upotreba
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
ES2738114T3 (es) 2010-02-11 2020-01-20 Ablynx Nv Métodos y composiciones para la preparación de aerosoles
EP2552962B1 (de) 2010-03-26 2016-03-23 Ablynx N.V. Einzelne, gegen cxcr7 gerichtete variable immunoglobulindomänen
MX2012013490A (es) 2010-05-20 2013-01-29 Ablynx Nv Materiales biologicos relacionados con her3.
WO2011161263A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Pharmaceutical compositions for cutaneous administration
ES2660895T3 (es) 2010-10-29 2018-03-26 Ablynx N.V. Método para la producción de dominios variables individuales de inmunoglobulina
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
EA037063B1 (ru) 2010-11-08 2021-02-01 Аблинкс Н.В. Cxcr2-связывающие полипептиды
EP2691418A1 (de) 2011-03-28 2014-02-05 Ablynx N.V. Bispezifische gegen cxcr4 gerichtete variable immglobulineinzeldomänen
US9468679B2 (en) 2011-03-28 2016-10-18 Ablynx N.V. Method for producing solid formulations comprising immunoglobulin single variable domains
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
US9534039B2 (en) 2011-05-09 2017-01-03 Ablynx N.V. Method for the production of immunoglobulin single variable domains
KR102072250B1 (ko) 2011-05-27 2020-03-02 아블린쓰 엔.브이. Ｒａｎｋｌ 결합 펩티드를 이용한 골 재흡수 억제
JP2014525736A (ja) 2011-06-23 2014-10-02 アブリンクス エン．ヴェー． ＩｇＥに対する免疫グロブリン単一可変ドメイン
EP2747782B1 (de) 2011-09-23 2018-01-17 Ablynx NV Verlängerte inhibition der interleukin-6-vermittelten signalisierung
PL2773671T3 (pl) 2011-11-04 2022-01-24 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerycznego z mutacjami w domenie fc
JP6351572B2 (ja) 2012-05-10 2018-07-04 ザイムワークス，インコーポレイテッド Ｆｃドメインに突然変異を有する免疫グロブリン重鎖のヘテロ多量体構築物
US9499634B2 (en) 2012-06-25 2016-11-22 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
EP2994530A4 (de) 2013-05-10 2016-11-16 Whitehead Biomedical Inst Proteinmodifizierung von lebenden zellen unter verwendung von sortase
EP2883883A1 (de) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutische Ziele und Mittel zur Behandlung von ischämiebedingten Reperfusionsschäden
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
AU2015329935B2 (en) 2014-10-10 2019-09-19 Ablynx N.V. Inhalation device for use in aerosol therapy of respiratory diseases
CA2963037A1 (en) 2014-10-10 2016-04-14 Vectura Gmbh Treatment of rsv infection
CN107406497A (zh) 2014-12-19 2017-11-28 埃博灵克斯股份有限公司 半胱氨酸连接的纳米抗体二聚体
CN108473561B (zh) 2015-11-27 2022-12-16 埃博灵克斯股份有限公司 抑制cd40l的多肽
SE543153C2 (en) 2016-05-19 2020-10-13 Biocool Ab Aqueous hydrogen peroxide solution obtained from a dry composition comprising sodium percarbonate for skin treatment
EP3468530A4 (de) 2016-06-10 2020-03-11 Clarity Cosmetics Inc. Nichtkomedogene formuliereungen zur haar- und kopfhautpflege und verfahren zur verwendung
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
IL317416A (en) 2016-11-16 2025-02-01 Ablynx Nv T cell-recruiting polypeptides capable of binding CD123 and TCR alpha/beta
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
BR112019017853A2 (pt) 2017-02-28 2021-04-27 Vib Vzw Meios e métodos para liberação oral de proteína
CA3062238A1 (en) 2017-05-11 2018-11-15 Vib Vzw Glycosylation of variable immunoglobulin domains
CN111032695B (zh) 2017-06-02 2024-06-25 默克专利股份有限公司 结合adamts的免疫球蛋白
MX2019014504A (es) 2017-06-02 2020-07-20 Merck Patent Gmbh Inmunoglobulinas de union a agrecano.
CN110997001A (zh) 2017-06-02 2020-04-10 默克专利股份有限公司 Mmp13结合免疫球蛋白
MX2019014397A (es) 2017-06-02 2020-02-10 Merck Patent Gmbh Polipeptidos que enlazan adamts5, mmp13 y agrecano.
CA3070253A1 (en) 2017-07-19 2019-01-24 Vib Vzw Serum albumin binding agents
EP4635987A3 (de) 2017-10-31 2026-01-14 Vib Vzw Neue antigenbindende chimäre proteine sowie verfahren und verwendungen davon
CN111670202A (zh) 2018-02-06 2020-09-15 埃博灵克斯股份有限公司 以免疫球蛋白单可变结构域治疗ttp初次发作的方法
EP3758742A1 (de) 2018-03-01 2021-01-06 Vrije Universiteit Brussel Menschliche pd-l1-bindende immunglobuline
JP7390729B2 (ja) 2018-03-23 2023-12-04 ユニヴェルシテ リブル ドゥ ブリュッセル Ｗｎｔシグナル伝達アゴニスト分子
EP4378485A3 (de) 2019-03-08 2024-08-28 LinXis B.V. Internalisierung von bindungsmolekülen, die auf rezeptoren abzielen, die an der zellproliferation oder zelldifferenzierung beteiligt sind
EP3976650A1 (de) 2019-05-28 2022-04-06 Vib Vzw Krebsbehandlung durch abzielen auf plexine im immunbereich
WO2020239934A1 (en) 2019-05-28 2020-12-03 Vib Vzw Cd8+ t-cells lacking plexins and their application in cancer treatment
GB201918279D0 (en) 2019-12-12 2020-01-29 Vib Vzw Glycosylated single chain immunoglobulin domains
CN113527488B (zh) 2020-04-22 2026-04-17 迈威(上海)生物科技股份有限公司 一种靶向人程序性死亡配体1（pd-l1）的单可变域抗体及其衍生物
WO2021229104A1 (en) 2020-05-15 2021-11-18 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
WO2022060223A1 (en) 2020-09-16 2022-03-24 Linxis B.V. Internalizing binding molecules
WO2022063947A1 (en) 2020-09-24 2022-03-31 Vib Vzw Combination of p2y6 inhibitors and immune checkpoint inhibitors
WO2022063957A1 (en) 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
PH12023500013A1 (en) 2020-12-04 2024-03-11 Tidal Therapeutics Inc Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
EP4294407A1 (de) 2021-02-17 2023-12-27 Vib Vzw Hemmung von slc4a4 bei der behandlung von krebs
CN117321076A (zh) 2021-02-19 2023-12-29 美国卫生及公众服务部代表 中和SARS-CoV-2的单结构域抗体
US20240261446A1 (en) 2021-05-17 2024-08-08 Université de Liège Anti-cd38 single domain antibodies in disease monitoring and treatment
EP4512826A3 (de) 2021-07-09 2025-04-02 Luxembourg Institute Of Health (LIH) Dimere proteinkomplexe und verwendungen davon
AR129560A1 (es) 2022-06-08 2024-09-04 Tidal Therapeutics Inc Lípidos catiónicos ionizables y nanopartículas lipídicas, y métodos de síntesis y uso de los mismos
WO2024008274A1 (en) 2022-07-04 2024-01-11 Universiteit Antwerpen T regulatory cell modification
JP2025523630A (ja) 2022-07-04 2025-07-23 ブイアイビー ブイゼットダブリュ 血液－脳脊髄液関門通過抗体
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
KR20250124145A (ko) 2022-12-21 2025-08-19 젠자임 코포레이션 항-pd-1×4-1bb 결합 단백질
WO2024156888A1 (en) 2023-01-27 2024-08-02 Vib Vzw Cd163-binding conjugates
EP4655323A1 (de) 2023-01-27 2025-12-03 Vrije Universiteit Brussel Cd8b-bindende polypeptide
WO2024208816A1 (en) 2023-04-03 2024-10-10 Vib Vzw Blood-brain barrier crossing antibodies
CN121511260A (zh) 2023-05-11 2026-02-10 非营利性组织佛兰芒综合大学生物技术研究所 SLC4A4/NBCe1抑制剂
WO2024251783A1 (en) 2023-06-05 2024-12-12 Sanofi Predicting thermal stabilities of immunoglobulin single variable domains using machine-learning models
EP4483951A1 (de) 2023-06-30 2025-01-01 Université de Liège Einzeldomänenantikörper zur hemmung der aktivität neutrophiler elastase
WO2025093509A1 (en) 2023-10-31 2025-05-08 Sanofi Electronic system for measuring parameters of a drug delivery device and method for localizing the electronic system
WO2025093510A1 (en) 2023-10-31 2025-05-08 Sanofi Electronic system
WO2025093512A1 (en) 2023-10-31 2025-05-08 Sanofi Electronic system
WO2025093511A1 (en) 2023-10-31 2025-05-08 Sanofi Electronic system for a drug delivery device
WO2025093683A1 (en) 2023-11-03 2025-05-08 Neuvasq Biotechnologies Sa Wnt7 signaling agonists
WO2025157888A1 (en) 2024-01-24 2025-07-31 Sanofi Electronic add-on module with transmission component
WO2025157891A1 (en) 2024-01-24 2025-07-31 Sanofi Electronic add-on module comprising a sensor arrangement
WO2025157890A1 (en) 2024-01-24 2025-07-31 Sanofi Electronic add-on module and assembly of an electronic add-on module and a drug delivery device
WO2025157886A1 (en) 2024-01-24 2025-07-31 Sanofi Electronic add-on module comprising a sensor arrangement
WO2025157893A1 (en) 2024-01-24 2025-07-31 Sanofi Electronic add-on module and assembly of an electronic add-on module and a drug delivery device
WO2025157887A1 (en) 2024-01-24 2025-07-31 Sanofi Electronic add-on module comprising electrically conductive elements providing a switch
WO2025157892A1 (en) 2024-01-24 2025-07-31 Sanofi Electronic add-on module comprising a sensor arrangement
WO2025157885A1 (en) 2024-01-24 2025-07-31 Sanofi Electronic add-on module and assembly of an electronic add-on module and a drug delivery device
EP4591905A1 (de) 2024-01-24 2025-07-30 Sanofi Elektronisches zusatzmodul und anordnung eines elektronischen zusatzmoduls und einer arzneimittelabgabevorrichtung
WO2025157884A1 (en) 2024-01-24 2025-07-31 Sanofi Electronic add-on module comprising a microswitch
US12138428B1 (en) 2024-01-24 2024-11-12 Sanofi Electronic add-on module and assembly of an electronic add-on module and a drug delivery device
WO2025157883A1 (en) 2024-01-24 2025-07-31 Sanofi Electronic add-on module with a mechanical coupling element
WO2025172500A1 (en) 2024-02-14 2025-08-21 Sanofi Method for determining the dose capturing accuracy
WO2025181125A1 (en) 2024-02-28 2025-09-04 Sanofi Attachment mechanism, module and assembly herewith
WO2025181154A1 (en) 2024-02-28 2025-09-04 Sanofi Attachment mechanism, module and assembly herewith
EP4609896B1 (de) 2024-02-28 2026-04-29 Sanofi Befestigungsmechanismus, modul und anordnung damit
US12357764B1 (en) 2024-02-28 2025-07-15 Sanofi Attachment mechanism, module and assembly herewith
EP4609897B1 (de) 2024-02-28 2026-02-18 Sanofi Befestigungsmechanismus, modul und anordnung damit
US12144969B1 (en) 2024-02-28 2024-11-19 Sanofi Attachment mechanism, module and assembly herewith
WO2025196180A1 (en) 2024-03-21 2025-09-25 Sanofi Electronic system
WO2025207599A1 (en) 2024-03-26 2025-10-02 Genzyme Corporation Medicament container for lyophilizable medicament
WO2025207603A1 (en) 2024-03-26 2025-10-02 Genzyme Corporation Medicament container for lyophilizable medicament
EP4623963B1 (de) 2024-03-28 2026-04-22 Sanofi Elektronisches zusatzmodul und anordnung eines elektronischen zusatzmoduls und einer arzneimittelabgabevorrichtung
EP4623956B1 (de) 2024-03-28 2026-05-13 Sanofi Befestigungsmechanismus, modul und anordnung damit
US12239828B1 (en) 2024-03-28 2025-03-04 Sanofi Attachment mechanism, module and assembly herewith
WO2025202308A1 (en) 2024-03-28 2025-10-02 Sanofi Electronic add-on module and assembly of an electronic add-on module and a drug delivery device
WO2025212968A1 (en) 2024-04-05 2025-10-09 Genzyme Corporation Fluid guide system usable for drug handling, e.g. for reconstitution, corresponding medical device, method and computer related items
WO2025212970A1 (en) 2024-04-05 2025-10-09 Genzyme Corporation Multi-vial adapters for reconstituting or diluting lyophilized or concentrated drug products
WO2025219231A1 (en) 2024-04-15 2025-10-23 Vib Vzw Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope
WO2025221759A1 (en) 2024-04-17 2025-10-23 Genzyme Corporation Reconstituable drug formulation, medicament container and method of preparing an injectable medicament
WO2025221761A2 (en) 2024-04-17 2025-10-23 Genzyme Corporation Medicament container and kit for reconstituting a lyophilized medicament
WO2025222101A1 (en) 2024-04-19 2025-10-23 Genzyme Corporation Reconstitution kit for preparing an injectable liquid medicament, system for preparing an injectable liquid medicament, methods of preparing an injectable liquid medicament
WO2025222112A1 (en) 2024-04-19 2025-10-23 Genzyme Corporation Adapter for a medicament container, preparation kit comprising an adapter and a medicament container and method of preparing an injectable liquid medicament
WO2025221983A1 (en) 2024-04-19 2025-10-23 Genzyme Corporation Medicament container, set of medicament containers, kit comprising a medicament container and an adapter and methods of preparing an injectable liquid medicament
WO2025229160A1 (en) 2024-05-01 2025-11-06 Commit Biologics Aps Engineered proteins that engage complement factor and a protein antigen, methods, and uses thereof
EP4647095B1 (de) 2024-05-10 2026-05-06 Sanofi Elektronisches zusatzmodul und anordnung eines elektronischen zusatzmoduls und einer arzneimittelabgabevorrichtung
WO2025233436A1 (en) 2024-05-10 2025-11-13 Sanofi Electronic add-on module and assembly of an electronic add-on module and a drug delivery device
WO2025233480A1 (en) 2024-05-10 2025-11-13 Sanofi Electronic system
US12186538B1 (en) 2024-05-10 2025-01-07 Sanofi Electronic add-on module and assembly of an electronic add-on module and a drug delivery device
WO2025237857A1 (en) 2024-05-13 2025-11-20 Sanofi Electronic circuit for monitoring operation of an injection device and method of recording operation of an injection device
US12357539B1 (en) 2024-05-16 2025-07-15 Genzyme Corporation Vial adapter and injection kit for withdrawing a liquid medicament from an injection vial
US12213944B1 (en) 2024-05-16 2025-02-04 Genzyme Corporation Fluid transfer device
US12171719B1 (en) 2024-05-16 2024-12-24 Genzyme Corporation Fluid transfer device
US12226371B1 (en) 2024-05-16 2025-02-18 Genzyme Corporation Fluid transfer device
WO2025242704A1 (en) 2024-05-22 2025-11-27 Sanofi Electronic module, assembly of an electronic module and a drug delivery device and method for switching an electronic module
US20250360263A1 (en) 2024-05-24 2025-11-27 Genzyme Corporation Drug delivery device for delivering at least one drug, optionally at least one reconstituted drug, medical device and medical system
WO2025247953A1 (en) 2024-05-31 2025-12-04 Sanofi Wearable electronic device and method of monitoring use of an injection device
WO2025247955A1 (en) 2024-05-31 2025-12-04 Sanofi Wearable electronic device and method of monitoring use of an injection device
US12329940B1 (en) 2024-06-06 2025-06-17 Sanofi Drug delivery device, assembly for a drug delivery device, method for assembling the drug delivery device and use of the drug delivery device
WO2025252454A1 (en) 2024-06-06 2025-12-11 Sanofi Drug delivery device, assembly for a drug delivery device, method for assembling the drug delivery device and use of the drug delivery device
WO2025257207A1 (en) 2024-06-11 2025-12-18 Sanofi Method for improving data accuracy of dose size data, a user equipment and a mobile application
WO2025257274A1 (en) 2024-06-12 2025-12-18 Sanofi Syringe masking cover and combination of such a syringe masking cover with a syringe
WO2025264592A1 (en) 2024-06-17 2025-12-26 Genzyme Corporation Preparation assembly and method of preparing a liquid medicament
WO2026030375A2 (en) 2024-07-30 2026-02-05 Genzyme Corporation Lipid nanoparticles and methods of manufacture and use thereof
WO2026027592A1 (en) 2024-08-01 2026-02-05 Sanofi Cap removal aid and assembly therewith
WO2026027628A1 (en) 2024-08-01 2026-02-05 Sanofi Drug delivery device usage detection
WO2026043981A1 (en) 2024-08-21 2026-02-26 Genzyme Corporation Preparation assembly and method of preparing a liquid medicament
WO2026043974A1 (en) 2024-08-21 2026-02-26 Genzyme Corporation Preparation assembly and method of preparing a liquid medicament
WO2026047140A1 (en) 2024-09-02 2026-03-05 Sanofi Drug delivery device and methods of assembling and use thereof
WO2026047142A1 (en) 2024-09-02 2026-03-05 Sanofi Drive subassembly for a drug delivery device, drug delivery device, and methods of assembling and use thereof
WO2026047141A1 (en) 2024-09-02 2026-03-05 Sanofi Drug subassembly for a drug delivery device, drug delivery device, and methods of assembling and use thereof
WO2026062214A1 (en) 2024-09-19 2026-03-26 Sanofi Formulations comprising lunsekimig
WO2026072557A2 (en) 2024-09-24 2026-04-02 Genzyme Corporation Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
WO2026068859A1 (en) 2024-09-30 2026-04-02 Université Libre de Bruxelles Wnt signaling agonist molecules in the treatment of a bone-related disease or disorder
WO2026077997A1 (en) 2024-10-08 2026-04-16 Sanofi Reusable cap for a drug delivery device and arrangement comprising the reusable cap
WO2026080873A1 (en) 2024-10-11 2026-04-16 Genzyme Corporation Adapter and injection kit
EP4730342A1 (de) 2024-10-18 2026-04-22 Sanofi Verfahren, system und vorrichtung zur titerschätzung für immunglobulin-einzeldomänenmoleküle
WO2026087207A1 (en) 2024-10-25 2026-04-30 Sanofi Training structure prediction neural networks using active learning
US12357538B1 (en) 2024-11-25 2025-07-15 Genzyme Corporation Vial adapter and injection kit for withdrawing a liquid medicament from an injection vial
US12377023B1 (en) 2024-12-02 2025-08-05 Genzyme Corporation Fluid transfer device
US12434008B1 (en) 2025-02-26 2025-10-07 Genzyme Corporation Lock ring for a medicament delivery device
US12420017B1 (en) 2025-02-26 2025-09-23 Genzyme Corporation Damping device for a medicament delivery device
US12539367B1 (en) 2025-02-26 2026-02-03 Genzyme Corporation Medicament delivery device
US12465697B1 (en) 2025-02-26 2025-11-11 Genzyme Corporation Medicament delivery device

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4147782A (en) * 1976-06-24 1979-04-03 William H. Rorer, Inc. Pharmaceutical detergent composition
WO2000003686A2 (en) * 1998-07-20 2000-01-27 Sarlo Peter V Acne treatment compositions
US6423746B1 (en) * 1999-07-03 2002-07-23 The William M. Yarbrough Foundation Urushiol induced contact dermatitis and method of use
US20020183284A1 (en) * 1999-07-03 2002-12-05 Yarbrough William M. Urushiol induced contact dermatitis solution

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1539031A (en) * 1975-02-22 1979-01-24 Beecham Group Ltd Pharmaceutical compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4147782A (en) * 1976-06-24 1979-04-03 William H. Rorer, Inc. Pharmaceutical detergent composition
WO2000003686A2 (en) * 1998-07-20 2000-01-27 Sarlo Peter V Acne treatment compositions
US6423746B1 (en) * 1999-07-03 2002-07-23 The William M. Yarbrough Foundation Urushiol induced contact dermatitis and method of use
US20020183284A1 (en) * 1999-07-03 2002-12-05 Yarbrough William M. Urushiol induced contact dermatitis solution

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2005018629A1 *

Also Published As

Publication number Publication date
JP2007521234A (ja) 2007-08-02
WO2005018629A1 (en) 2005-03-03
AU2003264053A1 (en) 2005-03-10
CA2535550A1 (en) 2005-03-03
EP1656128A1 (de) 2006-05-17

Similar Documents

Publication Publication Date Title
WO2005018629A1 (en) Treatment for acne vulgaris and method of use
US6423746B1 (en) Urushiol induced contact dermatitis and method of use
US4514385A (en) Anti-acne compositions
AU2012242682B2 (en) Sodium hypochlorite-based body wash compositions
JP3434435B2 (ja) ふけ形成抑制効果を有する毛髪化粧料組成物
US6197317B1 (en) Composition and method for the treatment of skin
MX2007005444A (es) Composiciones farmaceuticas topicas que contienen un compuesto antiacne y un compuesto antibiotico.
US10561626B2 (en) Method for treating urushiol induced contact dermatitis
MXPA06001668A (en) Treatment for acne vulgaris and method of use
JP2001504153A (ja) 殺菌性ソープバー
CA2614846A1 (en) Acne treatment
JP2668853B2 (ja) 台所用洗剤
WO2000069403A1 (en) Alpha amino acid composition and method for the treatment of skin
JP2001079568A (ja) 脱塩素剤
CN111743793A (zh) 一种洗手液及其制备方法
JP2004131503A (ja) 溶解性が高められたベータヒドロキシ酸とそれを用いて処方した高い効能の皮膚剥離剤
JPH0324443B2 (de)
JP3293692B2 (ja) ヨード配合砂場用殺菌剤組成物
Andersen et al. Occupational irritant contact folliculitis associated with triphenyl tin fluoride (TPTF) exposure.
RU2177028C1 (ru) Состав для удаления органических и бактериальных загрязнений
WO2004052358A1 (en) Urushiol induced contact dermatitis treatment and method of use
JPH0853339A (ja) 皮膚外用剤
JP2007502289A (ja) 刺咬性及び侵入性生物並びに寄生生物と蕁麻疹の治療用組成物、並びに使用方法
US20050037039A1 (en) Composition for treatment of tinea pedis and method of use
JP2005527601A (ja) 二糖類及び金属イオンによる、刺激の阻止のための方法及び組成物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060310

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20070126

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/085 20060101AFI20070122BHEP

Ipc: A61P 17/10 20060101ALI20070122BHEP

Ipc: A61K 31/198 20060101ALI20070122BHEP

Ipc: A61K 45/06 20060101ALI20070122BHEP

17Q First examination report despatched

Effective date: 20070404

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE WILLIAM M. YARBROUGH FOUNDATION

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WILLIAM M. YARBROUGH

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070817